Abstract
We studied the usefulness of Kremezin, an oral sorbent, in managing renal failure in diabetic patients, treating 28 diagnosed clinically with diabetic nephropathy to progressive renal failure with 2.4-6g/day of Kremezin for 6 months. Changes in serum creatinine (Cr) and other parameters were compared before and after treatment, with the following results:(1) Cr increase was blunted in 65.4%.(2) The mean slope of the I/Cr-time curve (dl/mg.week) was-0.0043 before and-0.0015 after treatment, indicating a significant reduction in steepness after treatment.(3) Maintenance doses of 6g (n=14) and 3 g (n=14) were compared. In the group with a daily dose of 6g, the steepness of the gradient was significantly reduced from-0.0050 before to-0.0011 after treatment.In the group with a dose of 3g, although the slope tended to become less steep after treatment, the difference was not significant.(4) Indoxyl sulfate was significantly lowered from 0.53±0.50mg/dl before to 0.34±0.40mg/dl after treatment in the 6g dosage group but did not change significantly in the 3g dosage group.These results indicate the beneficial effects of Kremezin for renal failure in diabetic patients. Kremezin administered at a daily dose of 6 g effectively blunts progression to renal failure in diabetic patients with chronic diabetic renal failure.
